Axitinib - Isotope Labelled Standards
References
FAQ's
References
- Kania, Robert Steven; Bender, Steven Lee; Borchardt, Allen J.; Braganza, John F.; Cripps, Stephan James; Hua, Ye; Johnson, Michael David; Johnson, Theodore Otto, Jr.; Luu, Hiep The; Palmer, Cynthia Louise; et al, Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use, WO0102369A2, Jan 11, 2001, Agouron Pharmaceuticals, Inc., United States (https://patents.google.com/patent/WO2001002369A2/en)
- Sparidans, Rolf W.; Iusuf, Dilek; Schinkel, Alfred H.; Schellens, Jan H. M.; Beijnen, Jos H., Liquid chromatography-tandem mass spectrometric assay for the light sensitive tyrosine kinase inhibitor axitinib in human plasma, Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, Volume: 877, Issue: 32, Pages: 4090-4096, 2009 DOI: ( 10.1016/j.jchromb.2009.10.024)
Frequently Asked Questions
2.What are the types of degradation products found in Axitinib?
Sulfone, isomeric, sulfoxide, and dimer impurities are found in Axitinib.
3.How do we characterize Axitinib degradation products?
Liquid chromatography-high resolution mass spectrometry and nuclear magnetic resonance spectroscopy are the methods to characterize Axitinib degradation products.
4.What is the source of process-related impurities in Axitinib?
Palladium-catalyzed reagents and residual solvents form process-related impurities in Axitinib.
Note: Products protected by valid patents by a manufacturer are not offered for sale in countries having patent protection. The sale of such products constitutes a patent infringement, and its liability is at the buyer's risk.